Table 1.
Study | Subjects (n) | Males n (%) | Age (years) | BMI (kg/m2) | Diabetes n (%) | Hypertension n (%) | Hypercholesterolaemia n (%) | Smokinga n (%) | SBP (mmHg) | DBP (mmHg) | CAD n (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
Ambrosino et al. [4] | 133 COVID-19 | 108 (81.2) | 61.6 | – | 21 (15.8) | 68 (51.1) | 12 (9.0) | 12 (9.0) | – | – | 19 (14.3) |
133 Controls | 107 (80.5) | 60.4 | – | 23 (17.3) | 74 (55.6) | 14 (10.5) | 12 (9.0) | – | – | 24 (18.0) | |
Çiftel et al. [31] | 38 COVID-19 | 20 (52.6) | 8.9 | 19.6 | 0 | 0 | 0 | 0 | 99.6 | 61.5 | 0 |
38 Controls | 20 (52.6) | 8.9 | 20.1 | 0 | 0 | 0 | 0 | 108.9 | 68.2 | 0 | |
Ergül et al. [32] | 63 COVID-19 | – | – | – | – | – | – | – | – | – | – |
29 Controls | – | – | – | 0 | 0 | 0 | – | – | – | 0 | |
Gao et al. [33] (a) | 86 COVID-19 | 32 (37.2) | 55.7 | 24.0 | 14 (16.3) | 32 (37.2) | 16 (18.6) | – | 131.0 | 76.3 | 13 (15.1) |
28 Controls | 10 (35.7) | 52.7 | 23.0 | 0 | 0 | 0 | – | 125.0 | 74.0 | 0 | |
Gao et al. [33] (b) | 86 COVID-19 | 32 (37.2) | 55.7 | 24.0 | 14 (16.3) | 32 (37.2) | 16 (18.6) | – | 131.0 | 76.3 | 13 (15.1) |
30 –Controls | 11 (36.7) | 58.7 | 24.0 | 2 (6.7) | 10 (33.3) | 9 (30.0) | – | 126.0 | 72.7 | 3 (10.0) | |
Jud et al. [17] (a) | 14 COVID-19 | 7 (50.0) | 68.7 | 29.4 | 0 | 6 (42.9) | 6 (42.9) | 6 (42.9) | – | – | 0 |
14 controls | 7 (50.0) | 30.7 | 23.8 | 0 | 0 | 0 | 8 (57.1) | – | – | 0 | |
Jud et al. [17] (b) | 14 COVID-19 | 7 (50.0) | 68.7 | 29.4 | 0 | 6 (42.9) | 6 (42.9) | 6 (42.9) | – | – | 0 |
14 Controls | 7 (50.0) | 66.9 | 27.6 | 4 (28.6) | 13 (92.9) | 12 (85.7) | 11 (78.6) | – | – | 8 (57.1) | |
Lambadiari et al. [34] (a) | 70 COVID-19 | 44 (62.9) | 54.5 | – | 0 | 0 | 0 | 16 (22.9)c | 129.7 | 78.2 | 0 |
70 Controls | 44 (62.9) | 54.8 | – | 0 | 0 | 0 | 21 (30.0)c | 126.6 | 80.7 | 0 | |
Lambadiari et al. [34] (b) | 70 COVID-19 | 44 (62.9) | 54.5 | – | 0 | 0 | 0 | 16 (22.9)c | 129.7 | 78.2 | 0 |
70 Controls | 44 (62.9) | 54.5 | – | 0 | 70 (100) | 0 | 18 (25.7)c | 145.3 | 89.9 | 0 | |
Mansiroglu et al. [37] | 80 COVID-19 | 32 (40.0) | 32.1 | 25.6 | 2 (2.5) | 2 (2.5) | 1 (1.3) | 19 (23.8) | 105.0 | 70.0 | 0 |
81 Controls | 41 (44.4) | 30.5 | 20.0 | 2 (2.5) | 2 (2.5) | 1 (1.2) | 23 (28.4) | 110.0 | 70.0 | 0 | |
Nandadeva et al. [35] (a) | 8 COVID-19 | 1 (12.5) | 24.0 | 26.0 | 0 | 0 | 0 | 0 | 111.0 | 70.0 | 0 |
12 Controls | 6 (50.0) | 23.0 | 23.0 | 0 | 0 | 0 | 0 | 112.0 | 66.0 | 0 | |
Nandadeva et al. [35] (b) | 8 COVID-19 | 5 (62.5) | 22.0 | 22.0 | 0 | 0 | 0 | 0 | 110.0 | 68.0 | 0 |
12 controls | 6 (50.0) | 23.0 | 23.0 | 0 | 0 | 0 | 0 | 112.0 | 66.0 | 0 | |
Oikonomou et al. [15] (a) | 55 COVID-19 | 32 (58.2) | 57.8 | – | 12 (21.8) | 21 (38.2) | 14 (25.5)b | – | 129.0 | 80.0 | 3 (5.5) |
55 Controls | 29 (52.7) | 62.6 | – | 17 (30.9) | 28 (50.9) | 15 (27.3)b | – | 135.0 | 80.0 | 3 (5.5) | |
Oikonomou et al. [15] (b) | 55 COVID-19 | 32 (58.2) | 57.8 | – | 12 (21.8) | 21 (38.2) | 14 (25.5)b | – | 132.0 | 81.0 | 3 (5.5) |
55 Controls | 29 (52.7) | 62.6 | – | 17 (30.9) | 28 (50.9) | 15 (27.3)b | – | 135.0 | 80.0 | 3 (5.5) | |
Ratchford et al. [16] | 11 COVID-19 | 4 (36.4) | 20.1 | 23.5 | 0 | 0 | 0 | 0 | 121.3 | 71.8 | 0 |
20 Controls | 5 (25.0) | 23.0 | 22.5 | 0 | 0 | 0 | 0 | 111.8 | 77.7 | 0 | |
Riou et al. [36] | 27 COVID-19 | 17 (63.0) | 57.3 | 29.7 | 7 (25.9) | 13 (48.1) | – | 6 (22.2) | 134.0 | 84.7 | – |
9 Controls | 5 (55.6) | 58.3 | – | – | – | – | – | – | – | – | |
Skow et al. [18] | 23 COVID-19 | 9 (39.1) | 23.0 | 25.3 | 0 | 0 | 0 | 0 | 109.0 | 67.0 | 0 |
13 Controls | 6 (46.1) | 26.0 | 25.7 | 0 | 0 | 0 | 0 | 113.0 | 69.0 | 0 |
BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; CAD: coronary artery disease.
Continuous data are reported as mean values, unless otherwise indicated. The minus sign indicates that the information has not been specifically provided and/or cannot be inferred from the text of the article.
aAny smoking history.
bDyslipidaemia.
cCurrent smokers.